Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017

BOSTON--()--Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will present 6-month data from a randomized, double-blind, placebo-controlled, dose-ranging study assessing the efficacy and safety of CNTX-4975 for the treatment of moderate to severe chronic knee pain associated with osteoarthritis, at the 11th Annual PAINWeek Meeting taking place September 5 – 9, 2017 at The Cosmopolitan of Las Vegas in Las Vegas, NV.

Full abstracts are available at https://www.painweek.org/painweek.html. Details of the poster presentation are listed below.

Abstract Title (#76): Efficacy and Safety of CNTX-4975 in Subjects With Moderate to Severe Osteoarthritis Knee Pain: A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Presentation Time: 6:30-8:30 p.m. PT, Thursday, September 7
Location: Level 3/Gracia 7 at The Cosmopolitan of Las Vegas

About CNTX-4975

CNTX-4975 is based on Centrexion’s proprietary STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI® is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while leaving the rest of the nerve fiber functioning as normal, and without the risks of toxicities of NSAIDs and injected steroids or the side effects, including abuse and addiction, associated with opioid treatments.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.

Contacts

Pure Communications, Inc.
Media Contact:
Julie Normart, +1-415-946-1087
jnormart@purecommunications.com
or
Investor Contact:
Luke Heagle, +1-910-726-1372
lheagle@purecommunications.com

Release Summary

Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain from Knee Osteoarthritis at PAINWeek.

Contacts

Pure Communications, Inc.
Media Contact:
Julie Normart, +1-415-946-1087
jnormart@purecommunications.com
or
Investor Contact:
Luke Heagle, +1-910-726-1372
lheagle@purecommunications.com